Program
lisocabtagene maraleucel
Also written as “Liso-cel”, “JCAR017” and “JCAR017 (lisocabtagene maraleucel)”.
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma · Lymphoma, Follicular, led by Bristol-Myers Squibb.
Furthest: phase 3, since Dec 19, 202310 company-led studies, 3 open or runningNext primary completion: Nov 26, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 103 open or running | phase 3since Dec 19, 2023 | Dec 11, 2015 | Nov 26, 2027phase 2 · NCT03331198 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2015First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT02631044 · 387 enrolled · United States
- Oct 29, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03331198 · 320 enrolled · United States, Canada
- Mar 23, 20182 phase 2 studies in Lymphoma, Non-HodgkinNCT03483103, NCT03484702
- Oct 18, 2018Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT03743246 · 21 enrolled · United States, France, Germany and more
- Nov 7, 2018Phase 2 study in Lymphoma, Non-HodgkinNCT03744676 · 104 enrolled · United States
- Jan 27, 2020Phase 2 study in Lymphoma, Non-HodgkinNCT04245839 · 276 enrolled · United States, Austria, Canada and more
- Dec 19, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06205290 · United States, Austria, Belgium and more
- Feb 26, 2024Phase 3 study in RecurrenceNCT06313996
- Jun 3, 2025Phase 2 study in LymphomaNCT07015242 · 65 planned · United States, France, Germany
Ahead
- Nov 26, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03331198
- Jan 9, 2028Primary completion: phase 2 study in LymphomaNCT07015242
- Sep 30, 2031Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT04245839
TargetBeta
CD19 →read by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| rapcabtagene autoleucel | Novartis | phase 2 | 8 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07015242Lymphoma · United States, France, Germany | 2 | Recruiting | Jan 9, 2028 | 65 |
| NCT06313996Recurrence | 3 | Withdrawn | Oct 16, 2031 | 0 |
| NCT06205290Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Belgium and more | 3 | Withdrawn | Oct 13, 2031 | 0 |
| NCT04245839Lymphoma, Non-Hodgkin · United States, Austria, Canada and more | 2 | Active, not recruiting | Sep 30, 2031 | 276 |
| NCT03744676Lymphoma, Non-Hodgkin · United States | 2 | Completed | Sep 22, 2023 | 104 |
| NCT03743246Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, France, Germany and more | 2 | Terminated | Jan 26, 2024 | 21 |
| NCT03484702Lymphoma, Non-Hodgkin · Austria, Belgium, Finland and more | 2 | Completed | Dec 15, 2023 | 113 |
| NCT03483103Lymphoma, Non-Hodgkin · United States | 2 | Completed | Sep 24, 2021 | 74 |
| NCT03331198Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada | 2 | Active, not recruiting | Nov 26, 2027 | 320 |
| NCT02631044Lymphoma, Non-Hodgkin · United States | 1 | Completed | May 16, 2024 | 387 |
How it is read
Names in the registry
- “Liso-cel”, 3 entries
- “JCAR017”, 3 entries
- “lisocabtagene maraleucel”, 2 entries
- “JCAR017 (lisocabtagene maraleucel)”, 1 entry
- “JCAR017 (lisocabtagene maraleucel) + ibrutinib”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 3 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
- Lymphoma, 1 study
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.